Box 1: Recent Trump Administration Obesity Drug Initiatives In November 2025, the Trump administration announced reaching a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1s for Medicare, Medicaid, and those purchasing the drugs directly from the manufacturers through a new TrumpRx website
Oxyntomodulin regulates resetting of the liver circadian clock by food
Competition centers on enhancing efficacy, weight-loss outcomes, dosing convenience, oral formulations, and cardiovascular benefits
Inject the diluent into the vial containing the lyophilized powder
Phase 2 trials investigated once-weekly subcutaneous doses ranging from 1 mg to 12 mg, administered via a gradual escalation schedule
Patients with PCOS are frequently characterized by other symptoms, such as obesity and IR (147)